Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CameL: Camrelizumab + Chemo in Non-Squamous NSCLC
NCT03134872Phase 3Completed
- Sponsor
- Hengrui
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started May 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03134872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134872.